The Hyperinsulinemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperinsulinemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Hyperinsulinemia by 14 companies/universities/institutes. The top development phase for Hyperinsulinemia is preclinical with seven drugs in that stage. The Hyperinsulinemia pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Hyperinsulinemia pipeline products market are: PegBio, Seneb BioSciences and Children’s Hospital of Philadelphia.

The key targets in the Hyperinsulinemia pipeline products market include Glucagon Receptor (GL R or GCGR), Glucagon Like Peptide 1 Receptor (GLP1R), and Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2).

The key mechanisms of action in the Hyperinsulinemia pipeline product include Glucagon Receptor (GL R or GCGR) Agonist with five drugs in Pre-Registration. The Hyperinsulinemia pipeline products include five routes of administration with the top ROA being Intravenous and four key molecule types in the Hyperinsulinemia pipeline products market including Synthetic Peptide, and Small Molecule.

Hyperinsulinemia overview

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequent hunger. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes insulin secretion inhibiting agents, diet, exercise, and other lifestyle changes.

For a complete picture of Hyperinsulinemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.